Dual

1. Males and females ≥ 18 years of age.

2. Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.

3. Insulin pump therapy for at least 6 months.

4. HbA1c ≤ 12% in the last 6 months.

1. Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2, GLP-1, Metformin, Acarbose, etc.…).

2. Severe hypoglycemic episode within one month of admission.

3. Severe diabetic ketoacidosis episode within one month of admission.

4. Pregnancy.

5. Known or suspected allergy to the study drugs.

6. Gastroparesis.

7. Use of prokinetic drugs that stimulate gastric emptying (domperidone, cisapride, metoclopramide).

8. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.

9. Recent (< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.

10. Current use of glucocorticoid medication.

11. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.

12. Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc.).